These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25200885)

  • 21. Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.
    Sonenthal PD; Ratshaa B; Chimbengo G; Rantleru T; Ngoni T; Barenbaum S; Platoff R; Steenhoff AP; Gross R
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):773-7. PubMed ID: 24664872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence seizures associated with efavirenz initiation.
    Strehlau R; Martens L; Coovadia A; Dandara C; Norman J; Maisel J; Kuhn L; Abrams EJ
    Pediatr Infect Dis J; 2011 Nov; 30(11):1001-3. PubMed ID: 21633320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz.
    Lowenhaupt EA; Matson K; Qureishi B; Saitoh A; Pugatch D
    Clin Infect Dis; 2007 Nov; 45(10):e128-30. PubMed ID: 17968817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efavirenz: a decade of clinical experience in the treatment of HIV.
    Maggiolo F
    J Antimicrob Chemother; 2009 Nov; 64(5):910-28. PubMed ID: 19767318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
    Scarsi KK; Cramer YS; Rosenkranz SL; Aweeka F; Berzins B; Coombs RW; Coughlin K; Moran LE; Zorrilla CD; Akelo V; Aziz M; Friedman RK; Gingrich D; Swaminathan S; Godfrey C; Cohn SE;
    Lancet HIV; 2019 Sep; 6(9):e601-e612. PubMed ID: 31498109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
    Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
    PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efavirenz as a psychotropic drug.
    Zareifopoulos N; Lagadinou M; Karela A; Pouliasi F; Economou I; Tsigkou A; Velissaris D
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10729-10735. PubMed ID: 33155233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
    Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
    Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
    Cooper DA; Heera J; Ive P; Botes M; Dejesus E; Burnside R; Clumeck N; Walmsley S; Lazzarin A; Mukwaya G; Saag M; van Der Ryst E
    AIDS; 2014 Mar; 28(5):717-25. PubMed ID: 24983542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System Toxicity.
    Bisaso KS; Bisaso KR; Mukonzo JK; Ette EI
    J Clin Pharmacol; 2020 Jun; 60(6):711-721. PubMed ID: 32096561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.
    Nylén H; Habtewold A; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
    Medicine (Baltimore); 2016 Aug; 95(34):e4631. PubMed ID: 27559961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
    Lennox JL; Dejesus E; Berger DS; Lazzarin A; Pollard RB; Ramalho Madruga JV; Zhao J; Wan H; Gilbert CL; Teppler H; Rodgers AJ; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Sklar P;
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):39-48. PubMed ID: 20404738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
    Kumar P; DeJesus E; Huhn G; Sloan L; Small CB; Edelstein H; Felizarta F; Hao R; Ross L; Stancil B; Pappa K; Ha B;
    BMC Infect Dis; 2013 Jun; 13():269. PubMed ID: 23741991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Annular erythema and photosensitivity as manifestations of efavirenz-induced cutaneous reactions: a review of five consecutive cases.
    Isaacs T; Ngwanya MR; Dlamini S; Lehloenya RJ
    J Antimicrob Chemother; 2013 Dec; 68(12):2871-4. PubMed ID: 23852540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances.
    Lapadula G; Bernasconi DP; Bai F; Focà E; Di Biagio A; Bonora S; Castelli F; Squillace N; Bandera A; Monforte AD; Migliorino GM; Gori A;
    AIDS; 2020 Jan; 34(1):53-61. PubMed ID: 31567160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-Rank Symptoms in Methamphetamine Psychosis and Schizophrenia.
    Shelly J; Uhlmann A; Sinclair H; Howells FM; Sibeko G; Wilson D; Stein DJ; Temmingh H
    Psychopathology; 2016; 49(6):429-435. PubMed ID: 27926911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efavirenz--still first-line king?
    Best BM; Goicoechea M
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):965-72. PubMed ID: 18624683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment.
    Brasher WP; Bvumbwe M; Kazembe PN
    Malawi Med J; 2020 Dec; 32(4):229-231. PubMed ID: 34457209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.